louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02558660: Evaluating Use of a Farmers Market Incentive Program Among Low-Income Health Center Patients
Official title: Evaluating Use of a Farmers Market Incentive Program Among Low-Income Health Center Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Food Insecurity
Non-use of Existing State-wide SNAP Incentive Program
Keywords: Supplemental Nutrition Incentive Program (SNAP)
economic incentive
Lead sponsor: University of Michigan
Sponsor class: OTHER
Collaborators: name: Robert Wood Johnson Foundation
First posted: 2015-09-24
Enrollment: 177
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP

Brief summary: The purpose of this study is to evaluate the impact of a brief clinic-based educational intervention on utilization of Double Up Food Bucks (DUFB)-a Michigan-wide Supplemental Nutrition Assistance Program (SNAP) healthy food incentive--among low income health center patients at a community health center in Southeast Michigan.

Detailed description: Study participants were provided a 3-5 minute explanation of DUFB, written program materials, and initial $10 market voucher. Participants were surveyed four times over five months, and a subset are also participating in post-intervention focus groups.

Eligibility criteria: Inclusion Criteria:

* patient or family member of patient
* at least 18 years of age
* currently SNAP-enrolled
* identifies as one of primary food shoppers for household
* English or Spanish-speaking

Exclusion Criteria:

* under 18
* not currently SNAP-enrolled
* not one of primary food shoppers for household
* unable to complete a telephone survey in English or Spanish
* unable to provide a working telephone number where they could be contacted

Primary outcomes:
measure: Prevalence of participant DUFB use over time, as assessed by an interviewer-administered survey using structured open-ended questions
timeFrame: 5 months
measure: Participant-perceived barriers and facilitators to DUFB use following educational intervention, as assessed by an interviewer-administered survey using structured open-ended questions and semi-structured focus group questions
timeFrame: 12 months
Secondary outcomes:
measure: Change from baseline fruit and vegetable consumption at 1.5 months, 3 months, and 5 months, as assessed by a validated 2 question fruit and vegetable screener
timeFrame: baseline, 1.5 months, 3 months, 5 months
Other outcomes:
Locations:
city: Ypsilanti
country: United States
facility: Ypsilanti Health Center, University of Michigan
state: Michigan
Study officials:
affiliation: University of Michigan
name: Alicia Cohen, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06717360: A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of AG2304T and AG2304R
Official title: A Multicenter, Randomized, Double-blinded, Active-controlled, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of AG2304T and AG2304R in Patients with Primary Hypercholesterolemia
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE3
Conditions: Hypercholesterolemia
Lead sponsor: Ahn-Gook Pharmaceuticals Co.,Ltd
Sponsor class: INDUSTRY
First posted: 2024-12-05
Enrollment: 140
Sex: ALL
Minimum age (years): 19
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of AG2304T and AG2304R in Patients with Primary Hypercholesterolemia


Eligibility criteria: Inclusion Criteria:

* Adults aged 19-80
* Patients with primary hypercholesterolemia
* Those who voluntarily written consent to participate in this clinical trial

Exclusion Criteria:

* The subject not meet the specified LDL-C level
* Other exclusions applied

Primary outcomes:
measure: LDL-C level
timeFrame: 8 weeks
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT05496660: The Effect of NHE and KT on the Hamstring Strength and Sprint Performance in Collegiate Sprinters
Official title: The Effect of the Nordic Hamstring Exercise and Kinesio Taping on the Hamstring Strength and Sprint Performance in Collegiate Sprinters
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hamstring Injury
Lead sponsor: Tianjin University of Sport
Sponsor class: OTHER
First posted: 2022-08-11
Enrollment: 40
Sex: MALE
Minimum age (years): 18
Maximum age (years): 25
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The invesitgators performed a randomized controlled trial on collegiate sprinters to explore the combined effect of the NHE and KT and randomly allocated the subjects into the experimental (NHE+KT) or control (NHE) group by an independent researcher using the sealed envelopes method.

To calculate the sample size, a Cohen's d effect size of 0.4, an alpha level of 0.05, a test power of 0.95 were configured to G\*Power software, at least 34 samples were computed. Considering the dropouts, 40 male collegiate sprinters were enrolled, explained the procedures of this study and voluntarily written informed consent. Inclusion criteria was that participants must be male, aged 18 years or older, training at the university level at least 4 times per week, with no history of lower limb injury within the last 6 months and no previous experience of the NHE or KT. Participants who had lower limb mobility limitation or injury especially HSI within 6 months and associated musculoskeletal, respiratory or cardiovascular diseases and was allergic to kinesio tape were excluded.


Eligibility criteria: Inclusion Criteria:

* Participants must be male, aged 18 years or older, training at the university level at least 4 times per week, with no history of lower limb injury within the last 6 months and no previous experience of the NHE or KT.

Exclusion Criteria:

* Participants who had lower limb mobility limitation or injury especially HSI within 6 months and associated musculoskeletal, respiratory or cardiovascular diseases and was allergic to kinesio tape were excluded.

Primary outcomes:
measure: isokinetic hamstring eccentric peak torque
timeFrame: 4-week
measure: 30m sprint performance
timeFrame: 4-week
Secondary outcomes:
measure: Hecc/Qcon Ratio
timeFrame: 4-week
Other outcomes:
Locations:
city: Tianjin
country: China
facility: Tianjin University of Sport
Study officials:
References:
Clinical trial NCT02012660: Relationship Between Heat Wave and Hyponatremia
Official title: Relationship Between Heat Wave and Moderate to Severe Hyponatremia in the Emergency Departement of Primary and Tertiary Care Teaching Hospital.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hyponatremia
Lead sponsor: University Hospital, Geneva
Sponsor class: OTHER
First posted: 2013-12-16
Enrollment: 28734
Sex: ALL
Minimum age (years): 16
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adults admitted to the emergency departement of a primary and tertiary care teaching hospital

Brief summary: The objective of this study is to explore the relationship between moderate to severe hyponatremia and heat.

Detailed description: We will explore the relationship between heat wave and moderate and severe hyponatremia in a population of adult patients admitted in the emergency department of a primary and tertiary care teaching urban hospital. We will compare the prevalence of hyponatremia between summer and winter periods. We will describe the types of observed hyponatremia and describe the characteristics of the patients suffering of moderate to severe hyponatremia.

Eligibility criteria: Inclusion Criteria:

* all adults (\> 16 y) with blood natremia measured

Exclusion Criteria:

* Patients without measure of natremia in the emergency department

Primary outcomes:
measure: Number of patients with moderate to severe hyponatremia
timeFrame: Natremia measured at admission in the ED
Secondary outcomes:
measure: Mortality
timeFrame: December 2011 to August 2013
measure: Hospital length of stay
timeFrame: December 2011 to August 2013
Other outcomes:
Locations:
city: Geneva
country: Switzerland
facility: Geneva University
Study officials:
affiliation: University Hospital, Geneva
name: Olivier T Rutschmann, MD, MPH
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00616460: ACRIPAB- Trial: Anti Coagulation Regimen In High Risk PAtients for Bleeding
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Hematologic Diseases
Keywords: safety
efficacy
Lead sponsor: HaEmek Medical Center, Israel
Sponsor class: OTHER
First posted: 2008-02-15
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To determine the safety/efficacy of Bivallirudin Vs unfractionated heparin (UFH) on top of dual antiplatelet therapy in patients with high tendency for bleeding during urgent and elective PCI.


Eligibility criteria: Inclusion Criteria:

Inclusion criteria (any of the following):

* ≥75 years
* Creatinin clearance rate \< 60 ml per minute
* Anemia (Hb 9-11 mg%)
* Hypertension: BP \> 180/95 mmHg but less than 210/110 m Hg
* Diabetic Pts
* Steroid treated Pts
* Recent (within 6 weeks) non major surgery
* Pts with hematological disorders associated with tendency for bleeding like Thrombocytopenia (platelets 50000-150000) included TTP;

Exclusion Criteria:

Exclusion criteria:

* Age \< 18 year
* Acute STEMI (Primary PCI)\*
* Rescue angioplasty \<12h after lytic therapy\*
* Active bleeding
* S.C LMWH \< 8 hours or UFH \< 4 hours before PCI
* Using IIb /IIIa as an upstream therapy before PCI
* PCI which will be involved with obligatory IIb /IIIa therapy:

(thrombotic complication, occlusive dissection)

* INR\>1.5 on day of cathetrization
* Bolus of 600mg of Clopidogrel before PCI
* Current pregnancy or women in reproductive age without contraceptives
* Hypersensitivity to heparin or bivalirudin or its components \*(possible using IIB/IIIA)

Primary outcomes:
measure: End points: Primary :Major & minor bleeding Port of entry related complications
timeFrame: 30 days
Secondary outcomes:
measure: End points: Secondary: 30 days MACE
timeFrame: 30 days
Other outcomes:
Locations:
city: Afula
country: Israel
facility: Heart Institute haEmek Medical Center
Study officials:
affiliation: Heart Institute HaEmek medical center
name: Yoav Turgeman, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05811260: MFR Versus PFS Techniques on Pain,Range of Motion And Disability in Chronic Non Specific Low Back Pain.
Official title: Effects of Myofascial Release Versus Post Facilitation Stretch Techniques on Pain,Range of Motion And Disability in Chronic Non Specific Low Back Pain.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Chronic Non Specific Low Back Pain
Keywords: Chronic pain,myofascial release technique, Postfacilitation stretch,Technique and low back pain.
Lead sponsor: Riphah International University
Sponsor class: OTHER
First posted: 2023-04-13
Enrollment: 28
Sex: ALL
Minimum age (years): 40
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To compare effect of myofascial Release versus post facilitation stretch in term of pain ,range of motion and disability in chronic non specific low back pain in patients.


Eligibility criteria: Inclusion Criteria:

* Male and female adults already diagnosed with LBP
* Between ages group of 40-55 years.

Exclusion Criteria:

* Patients who had LBP originating from various pathologies, such as presence of
* cord compression,
* radiculopathy,
* osteoporosis,

Primary outcomes:
measure: . Numeric pain rating scale
timeFrame: 4 weeks
Secondary outcomes:
measure: Inclinometer
timeFrame: 4 weeks
Other outcomes:
measure: Modified Oswestry Disability index
timeFrame: 4 weeks
Locations:
city: Layyah
country: Pakistan
facility: DHQ
state: Punjab
Study officials:
affiliation: Study principal Investigator
name: Muhammad Sanaullah, MS
role: PRINCIPAL_INVESTIGATOR
References:
citation: Foster NE, Anema JR, Cherkin D, Chou R, Cohen SP, Gross DP, Ferreira PH, Fritz JM, Koes BW, Peul W, Turner JA, Maher CG; Lancet Low Back Pain Series Working Group. Prevention and treatment of low back pain: evidence, challenges, and promising directions. Lancet. 2018 Jun 9;391(10137):2368-2383. doi: 10.1016/S0140-6736(18)30489-6. Epub 2018 Mar 21.
citation: Hartvigsen J, Hancock MJ, Kongsted A, Louw Q, Ferreira ML, Genevay S, Hoy D, Karppinen J, Pransky G, Sieper J, Smeets RJ, Underwood M; Lancet Low Back Pain Series Working Group. What low back pain is and why we need to pay attention. Lancet. 2018 Jun 9;391(10137):2356-2367. doi: 10.1016/S0140-6736(18)30480-X. Epub 2018 Mar 21.
Clinical trial NCT05999760: Retention, Chewing Efficiency and Masticatory Performance of Partial Dentures Opposing Implant Retained Prosthesis.
Official title: Retention, Chewing Efficiency and Masticatory Performance of Maxillary Flexible Versus Computer Aided Design/Computer Aided Manufacture(CAD/CAM) Partial Dentures Opposing Fixed Implant Retained Prosthesis.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Implant Site Reaction
Implant Complication
Keywords: Retention
Chewing efficiency
Removable Prosthodontics
Lead sponsor: National Research Centre, Egypt
Sponsor class: OTHER
First posted: 2023-08-21
Enrollment: 22
Sex: MALE
Minimum age (years): 40
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study aims to evaluate retention ,chewing efficiency and masticatory performance of flexible versus CAD/CAM partial dentures opposing to fixed implant retained restorations.

Detailed description: in this study 22 patients will be selected following inclusion and exclusion criteria. The patients will be divided randomly into two groups.

Group I patients will receive Versacrylic removable partial denture. group II patients will receive CAD/CAM removable partial denture all patients will be given the home care instructions at night and brush cleaning of the dentures.

Measurements of retention using universal testing machine, masticatory performance using T-scan III computerized system and chewing efficiency using chewing function questionnaire

Eligibility criteria: Inclusion Criteria:

* Non-smoker male Patients
* Age ranging from 40-50 years.
* Highly cooperative and motivated patients.
* Patients Systemically free from any immunosuppressive diseases.
* Patients free from Diabetes, Hypertension, Cancer, any mental or physical diseases.
* Patients not receiving any Radiotherapy or chemotherapy treatment.

Exclusion Criteria:

* Female patients
* Smoker patients.
* Age exceeding 50 years
* Uncooperative and unmotivated patients.

Primary outcomes:
measure: evaluation of change of retention of versacrylic and CAD/CAM partial denture
timeFrame: on day 1 ,1 month and 2months of prosthesis delivery
measure: evaluation of change of chewing efficiency of versacrylic and CAD/CAM partial denture
timeFrame: on day 1 ,1 month and 2months of prosthesis delivery
measure: evaluation of change of masticatory performance of versacrylic and CAD/CAM partial denture
timeFrame: on day 1,1 month and 2months of prosthesis delivery
Secondary outcomes:
Other outcomes:
Locations:
city: Giza
country: Egypt
facility: National Research Centre
Study officials:
affiliation: National Research Centre, Egypt
name: Menatallah Elhotieby, Researcher
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06665360: Identify the State of Laminae Milling by Sound
Official title: Sound Timbre-based Milling Status Identification in Robotic Vertebral Lamina Milling
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Spinal Degenerative Diseases
Lead sponsor: Tianjin Medical University General Hospital
Sponsor class: OTHER
Collaborators: name: Nankai University
First posted: 2024-10-30
Enrollment: 6
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with spinal stenosis requiring surgery

Brief summary: After verifying the signals collected in the laboratory, the investigators performed a preliminary verification in the surgery, in which the sound pressure signals of lamina milling were collected during the surgery to identify milling status.

Detailed description: The sound of milling cortical bone and cancellous bone were recorded during posterior spinal decompression.

Eligibility criteria: Inclusion Criteria:

1. Patients with myelopathy caused by spinal stenosis who had undergone posterior decompression.

Exclusion Criteria:

1. Receipt of surgery using an anterior approach or circumferential spinal cord decompression through a posterior approach;
2. Experience of trauma;
3. History of spinal tumor;
4. Previous spinal surgery;

Primary outcomes:
measure: Amplitude of sound pressure
timeFrame: The sound pressure signals were collected during the operation in 6 cases, an average of 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Tianjin
country: China
facility: Tianjin Medical University General Hospital
state: Tianjin
Study officials:
References:
Clinical trial NCT06795360: Weight Changes After Incretin-mimetics
Official title: Weight Changes After Incretin-mimetics
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Obesity and Obesity-related Medical Conditions
Keywords: obesity
weight loss
weight gain
Lead sponsor: Medical College of Wisconsin
Sponsor class: OTHER
Collaborators: name: University of Wisconsin, Milwaukee
First posted: 2025-01-28
Enrollment: 52
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: The goal of this study is to identify people at risk of weight regain after stopping an injectable weight loss drug. The main question the investigators aim to answer is: Can weight regain be predicted by measuring circulating Agouti-related peptide, a small protein coming from the brain?

Detailed description: This study will enroll people who are taking an injectable weight loss drug, have lost weight with the help of this drug, and are required by their health insurance plan to discontinue treatment. Participants will first be screened for health conditions that would prevent them from entering the study. Once enrolled, participants will be asked to have the following testing while still on the injectable weight loss drug: body weight measurement, body composition (fat and lean mass), resting energy expenditure (calories burned), multiple blood draws after overnight fast and after drinking and nutritional shake urine collection, urine collection, measurement of heart rate, measurement of physical activity and sleep, questionnaires. Participants will then stop taking the injectable weight loss drug when the prescription runs out, and the same tests will be repeated 3 months later.

Eligibility criteria: Inclusion Criteria:

* adults 18 years or older
* men and women
* prescribed an incretin-mimetic for weight loss and for whom insurance coverage for this specific drug will lapse
* any ethnicity

Exclusion Criteria:

* weight \> or = 400 lb
* type 1 or type 2 diabetes
* patients taking steroid medications
* anemia
* heart disease
* advanced kidney disease (CKD stage 4 and 5)
* decompensated liver disease
* hyperthyroidism
* untreated hypothyroidism
* active cancer
* post solid organ or bone marrow transplant
* HIV/AIDS
* pregnancy/plan for pregnancy in the next 6 months
* breastfeeding
* post-menopausal women
* current smoker
* current recreational drug use
* night shift or rotating shift workers

Primary outcomes:
measure: weight change
timeFrame: 3 months
measure: fasting and post-prandial circulating AgRP
timeFrame: 3 months
Secondary outcomes:
measure: subjective hunger ratings
timeFrame: 3 months
measure: resting metabolic rate (RMR)
timeFrame: 3 months
measure: RMR adaptation
timeFrame: 3 months
measure: body composition
timeFrame: 3 months
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01690260: Parallel Study Between BMP-2 and Autologous Bone Graft After Ilizarow Treatment
Official title: Bone Morphogenetic Protein-2 Increase as Substitute for Autologous Bone Graft After Ilizarow Treatment for Arthritis and Degenerative Bones.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Bone Degenerative Changes
Osteoarthritis
Degenerative Disorder of Bone
Keywords: Bone
Morphogenetic
Protein
Ilizarow
Autologous
Osteoarthritis
Lead sponsor: Northern Orthopaedic Division, Denmark
Sponsor class: OTHER
Collaborators: name: Medtronic
name: Center for Clinical and Basic Research (CCBR A/S).
First posted: 2012-09-21
Enrollment: 41
Sex: ALL
Minimum age (years): 20
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Results of growth factors indicate that Bone Morphogenetic Proteins (BMP) have an exceptional ability to stimulate different characteristics of mesenchymale cells to osseous cells. Local application of BMP results in an increase of osseous tissue regardless of the location of the growth factor.

5 years clinical studies show that BMP's can stimulate an increase of osseous tissue and improve clinical results when autologous bone graft is reduced or removed.

The purpose of this study is to examine whether recombinant growth factor BMP-2 can replace autologous bone graft in order to stimulating ossification during transplantation of osseous tissue.


Eligibility criteria: Inclusion Criteria:

* Hospitalised for autologous bone graft based on Ilizarow treatment.
* Age between 20 and 70 years.

Exclusion Criteria:

* Rheumatoid osteoarthritis
* Malignant disease
* Current hormone treatment (glucocorticoid, parathyreoidea, thyreoidea)
* Pregnancy
* Abuse of drugs and alcohol
* Need of long-term NSAID treatment
* Breastfeeding women

Primary outcomes:
measure: Visible radiological signs of healing after 6 months.
timeFrame: An expected average of 6 months
Secondary outcomes:
measure: Change in serologic bone markers
timeFrame: An expected average of 6 months
Other outcomes:
Locations:
city: Aalborg
country: Denmark
facility: Orthopaedic Surgery Research Unit, Aalborg University Hospital
Study officials:
affiliation: Orthopaedic Surgery Research Unit, Aalborg University Hospital, Denmark
name: Knud S. Christensen, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Medtronic Inc., Watford
name: David Donnell, Advisor
role: STUDY_CHAIR
affiliation: Center for Clinical and Basic Research, Aalborg, Denmark (CCBR A/S)
name: Hans H. Hoeck, MD, Ph.D.
role: STUDY_CHAIR
References: